190 related articles for article (PubMed ID: 34680409)
1. Long-Term Pharmacokinetics of Dalbavancin in ABSSSI and Osteoarticular Settings: A Real-Life Outpatient Context.
De Nicolò A; Stroffolini G; Antonucci M; Mula J; De Vivo ED; Cusato J; Palermiti A; Cariti G; Di Perri G; Corcione S; De Rosa FG; D'Avolio A
Biomedicines; 2021 Sep; 9(10):. PubMed ID: 34680409
[TBL] [Abstract][Full Text] [Related]
2. Clinical Effectiveness and Pharmacokinetics of Dalbavancin in Treatment-Experienced Patients with Skin, Osteoarticular, or Vascular Infections.
Stroffolini G; De Nicolò A; Gaviraghi A; Mula J; Cariti G; Scabini S; Manca A; Cusato J; Corcione S; Bonora S; Di Perri G; De Rosa FG; D'Avolio A
Pharmaceutics; 2022 Sep; 14(9):. PubMed ID: 36145630
[TBL] [Abstract][Full Text] [Related]
3. Use of Dalbavancin in Skin, Bone and Joint Infections: A Real-Life Experience in an Italian Center.
Brescini L; Della Martera F; Morroni G; Mazzanti S; Di Pietrantonio M; Mantini P; Candelaresi B; Pallotta F; Olivieri S; Iencinella V; Castelletti S; Cocci E; Polo RG; Veccia S; Cirioni O; Tavio M; Giacometti A
Antibiotics (Basel); 2021 Sep; 10(9):. PubMed ID: 34572711
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of dalbavancin in the treatment of acute bacterial skin and skin structure infections (ABSSSIs) and other infections in a real-life setting: data from an Italian observational multicentric study (DALBITA study).
Bai F; Aldieri C; Cattelan A; Raumer F; Di Meco E; Moioli MC; Tordato F; Morelli P; Borghi F; Rizzi M; Van Hauwermeiren E; Castelli F; Migliorino G; Menzaghi B; Rizzardini G; Saracino A; Cascio A; Puoti M; d'Arminio Monforte A; Marchetti G
Expert Rev Anti Infect Ther; 2020 Dec; 18(12):1271-1279. PubMed ID: 32797758
[TBL] [Abstract][Full Text] [Related]
5. In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
Andes D; Craig WA
Antimicrob Agents Chemother; 2007 May; 51(5):1633-42. PubMed ID: 17307987
[TBL] [Abstract][Full Text] [Related]
6. Dalbavancin in the treatment of acute bacterial skin and skin structure and other infections: a safety evaluation.
Righi E; Visentin A; Meroi M; Carrara E; Tacconelli E
Expert Opin Drug Saf; 2022 Sep; 21(9):1171-1181. PubMed ID: 36093622
[TBL] [Abstract][Full Text] [Related]
7. Clinical Pharmacokinetics and Pharmacodynamics of Dalbavancin.
Molina KC; Miller MA; Mueller SW; Van Matre ET; Krsak M; Kiser TH
Clin Pharmacokinet; 2022 Mar; 61(3):363-374. PubMed ID: 34931283
[TBL] [Abstract][Full Text] [Related]
8. Real-World Use of Dalbavancin for Treatment of Soft Tissue and Bone Infection in Children: Safe, Effective and Hospital-Time Sparing.
Caselli D; Mariani M; Colomba C; Ferrecchi C; Cafagno C; Trotta D; Carloni I; Dibello D; Castagnola E; Aricò M
Children (Basel); 2024 Jan; 11(1):. PubMed ID: 38255391
[TBL] [Abstract][Full Text] [Related]
9. Off-label use of dalbavancin in children: a case series.
Gamell A; Velasco-Arnaiz E; López-Ramos MG; Ríos-Barnés M; Simó-Nebot S; Fumadó V; Noguera-Julián A; Fortuny C
J Antimicrob Chemother; 2024 Jul; ():. PubMed ID: 38958260
[TBL] [Abstract][Full Text] [Related]
10. A cost-minimization analysis of dalbavancin compared to conventional therapy for the outpatient treatment of acute bacterial skin and skin-structure infections.
Turco NJ; Kane-Gill SL; Hernandez I; Oleksiuk LM; D'Amico F; Pickering AJ
Expert Opin Pharmacother; 2018 Mar; 19(4):319-325. PubMed ID: 29509504
[TBL] [Abstract][Full Text] [Related]
11. Dalbavancin for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in pediatric patients: a case series.
Garbo V; Condemi A; Albano C; Polara VF; Parrino R; Macaluso A; Venuti L; Colomba C
Infez Med; 2024; 32(2):231-240. PubMed ID: 38827834
[TBL] [Abstract][Full Text] [Related]
12. Single-dose dalbavancin and patient satisfaction in an outpatient setting in the treatment of acute bacterial skin and skin structure infections.
Rappo U; Gonzalez PL; Puttagunta S; Akinapelli K; Keyloun K; Gillard P; Liu Y; Dunne MW
J Glob Antimicrob Resist; 2019 Jun; 17():60-65. PubMed ID: 30797084
[TBL] [Abstract][Full Text] [Related]
13. Dalbavancin: A Novel Lipoglycopeptide Antibiotic with Extended Activity Against Gram-Positive Infections.
Smith JR; Roberts KD; Rybak MJ
Infect Dis Ther; 2015 Sep; 4(3):245-58. PubMed ID: 26341488
[TBL] [Abstract][Full Text] [Related]
14. Dalbavancin for the treatment of acute bacterial skin and skin structure infections.
Ramdeen S; Boucher HW
Expert Opin Pharmacother; 2015; 16(13):2073-81. PubMed ID: 26239321
[TBL] [Abstract][Full Text] [Related]
15. Clinical efficacy of dalbavancin for the treatment of acute bacterial skin and skin structure infections (ABSSSI).
Leuthner KD; Buechler KA; Kogan D; Saguros A; Lee HS
Ther Clin Risk Manag; 2016; 12():931-40. PubMed ID: 27354809
[TBL] [Abstract][Full Text] [Related]
16. The role of long-acting antibiotics in the clinical practice: a narrative review.
Micheli G; Chiuchiarelli M; Taccari F; Fantoni M
Infez Med; 2023; 31(4):449-465. PubMed ID: 38075413
[TBL] [Abstract][Full Text] [Related]
17. Review: A Safety Profile of Dalbavancin for On- and Off-Label Utilization.
Simonetti O; Rizzetto G; Molinelli E; Cirioni O; Offidani A
Ther Clin Risk Manag; 2021; 17():223-232. PubMed ID: 33790563
[TBL] [Abstract][Full Text] [Related]
18. Intravenous and Intraperitoneal Pharmacokinetics of Dalbavancin in Peritoneal Dialysis Patients.
Van Matre ET; Teitelbaum I; Kiser TH
Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32122898
[TBL] [Abstract][Full Text] [Related]
19. Financial Analysis of Dalbavancin for Acute Bacterial Skin and Skin Structure Infections for Self-Pay Patients.
Pizzuti AG; Murray EY; Wagner JL; Gaul DA; Bland CM; Jones BM
Infect Dis Ther; 2020 Dec; 9(4):1043-1053. PubMed ID: 33083894
[TBL] [Abstract][Full Text] [Related]
20. Single-Dose Dalbavancin: A Review in Acute Bacterial Skin and Skin Structure Infections.
Garnock-Jones KP
Drugs; 2017 Jan; 77(1):75-83. PubMed ID: 27988870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]